Search Results
Jun 18, 2025, 07:27 ET A CONTAGEM REGRESSIVA COMEÇOU: FALTAM DUAS SEMANAS PARA A HUBLOT DISPARAR O CRONÔMETRO DO CAMPEONATO EUROPEU DE FUTEBOL FEMININO 2025™
Exceptional Timepieces superam todas as expectativas com criações relojoeiras sem precedentes. Com sua disruptiva abordagem de desafiar as convenções, o DNA da Hublot é traduzido nos movimentos Unico, Meca-10 e Turbilhão que ela mesma desenvolveu internamente, adicionando mais uma camada de significado à
More news about: Hublot SA
Jun 18, 2025, 07:18 ET IL CONTO ALLA ROVESCIA È INIZIATO: MANCANO DUE SETTIMANE AL CALCIO DI INIZIO DI UEFA EURO 2025™ FEMMINILE
gli Exceptional Timepiece superano le aspettative per creare segnatempo senza precedenti. Con il suo approccio dirompente che sfida le convenzioni, il DNA di Hublot è trascritto nei movimenti di manifattura di Unico, Meca-10 e Tourbillon, per aggiungere un ulteriore livello di significato all'Art of Fusion.
More news about: Hublot SA
Jun 18, 2025, 07:06 ET DER COUNTDOWN LÄUFT: IN ZWEI WOCHEN STARTET HUBLOT DIE UHR FÜR DIE UEFA WOMEN'S EURO 2025™
schaffen. Auch die in der eigenen Manufaktur entwickelten und produzierten Uhrwerke – Unico, Meca-10 und Tourbillonkaliber – tragen die rebellische DNA in sich, die Hublot dazu antreibt, die Konventionen ein ums andere Mal herauszufordern. Damit fügen sie der Kunst der Fusion eine weitere Bedeutungsebene
More news about: Hublot SA
Jun 18, 2025, 07:00 ET KLOTHO NEUROSCIENCES (KLTO) ANNOUNCES MUTUAL TERMINATION OF SHARE EXCHANGE AGREEMENT WITH SKYBELL TECHNOLOGIES (SKYBELL), TO CONTINUE ITS FOCUS ON THERAPEUTICS AND LONGEVITY PROGRAMS
such as ALS, Alzheimer's, and Parkinson's disease. The company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The company is managed by a team of individuals and advisors who are highly experienced
More news about: Klotho Neurosciences, Inc.
Jun 18, 2025, 07:00 ET THE COUNTDOWN IS ON: TWO WEEKS TO GO UNTIL HUBLOT STARTS THE CLOCK ON UEFA WOMEN'S EURO 2025™
Exceptional Timepieces overwrite expectations to create unprecedented horological objects. With its disruptive approach of challenging convention, Hublot's DNA is transcribed in the Unico, Meca-10 and tourbillon in-house movements, to add another tier of meaning to the Art of Fusion. Alchemy is ingrained
More news about: Hublot SA
Jun 18, 2025, 07:00 ET THE COUNTDOWN IS ON: TWO WEEKS TO GO UNTIL HUBLOT STARTS THE CLOCK ON UEFA WOMEN'S EURO 2025™
Exceptional Timepieces overwrite expectations to create unprecedented horological objects. With its disruptive approach of challenging convention, Hublot's DNA is transcribed in the Unico, Meca-10 and tourbillon in-house movements, to add another tier of meaning to the Art of Fusion. Alchemy is ingrained
More news about: Hublot SA
Jun 17, 2025, 18:53 ET Ira Subaru of Danvers Makes $40,000 Donation to Essex County Habitat for Humanity
construct the home," said Roscoe Robinson, General Manager of Ira Subaru. "Supporting local communities is part of our DNA, and our donation represents Ira Subaru and Group 1's legacy of positive change that will benefit future generations." Ira Subaru is part of
More news about: Group 1 Automotive, Inc.
Jun 17, 2025, 14:17 ET Human Longevity, Inc. Expands Pancreatic Cancer Prevention Commitment with $1 Million Pledge for Qualified Members
development of what HLI believes to be one of the most advanced early detection algorithms for pancreatic cancer available today, including a new proprietary DNA-based pancreatic cancer screening test. In most cases, our multi-modal screening approach helps detect cancer at a stage when it is curable. But
More news about: Human Longevity, Inc.
Jun 17, 2025, 10:30 ET Biosimilars Market worth US$72.29 billion by 2035 with 7.5% CAGR | MarketsandMarkets™
therapeutics for managing autoimmune diseases, malignancies, chronic conditions, and infectious diseases. These agents are engineered through recombinant DNA (rDNA) technology, enabling them to selectively target specific antigens or cellular receptors, which enhances their therapeutic efficacy and specificity.
More news about: MarketsandMarkets
Jun 17, 2025, 09:06 ET Russell Reynolds Associates Introduces Strategy Decode and Activation to Address the Leadership Gap in Business Transformation
approach ensures transformations succeed because leaders truly own and can execute them, creating lasting change that becomes part of organizational DNA. RRA equips leaders to drive the urgent, impactful transformations essential for thriving in today's dynamic landscape. About Russell Reynolds
More news about: Russell Reynolds Associates
Jun 17, 2025, 09:00 ET Haircare Disruptor isima Raises Debut Series in Excess of $12 Million to Support Unprecedented Market Penetration at Launch
launch with availability in nearly 30 global markets upon its debut. "isima is what the future of beauty looks like—global by design, inclusive by DNA, and built for scale," said Amir Karimpour, Managing Partner at northstar.vc. "At northstar.vc, we're proud to co-lead
More news about: isima
Jun 17, 2025, 07:01 ET Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI
candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram-positive specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that
More news about: Acurx Pharmaceuticals, Inc.
Jun 17, 2025, 06:53 ET European Direct-to-Consumer Genetic Testing Market to Reach USD 3.78 Billion by 2035, Says Meticulous Research®
growing understanding of gene-diet interactions. Next-Generation Sequencing (NGS) Experiencing Highest Growth by Technology The DNA Microarrays segment is expected to dominate the overall European DTC genetic testing market in 2025, primarily due to its cost-effectiveness and suitability
More news about: Meticulous Market Research Pvt. Ltd.
Jun 16, 2025, 15:11 ET AS BAHAMAS TOMAM MEDIDAS AGRESSIVAS PARA COMBATER A CRISE DOS RECIFES DE CORAL
resiliência marinha -- -- O primeiro banco de genes de corais das Bahamas a preservar o DNA, propagar e replantar corais para reverter a devastação causada pelo aumento da temperatura dos oceanos e por uma doença que se espalha rapidamente --
More news about: Atlantis, Paradise Island
Jun 16, 2025, 15:03 ET THE BAHAMAS TAKES AGGRESSIVE STEPS TO COMBAT CORAL REEF CRISIS
conservation and marine resilience -- -- The Bahamas' first coral gene bank to preserve DNA, propagate and replant coral to reverse devastation from rising ocean temperatures and a rapidly spreading disease -- PARADISE
More news about: Atlantis, Paradise Island
Jun 16, 2025, 11:11 ET Translators' Voices: The culture of planning is rooted in China's DNA
and the people first, this plan will certainly be successful. Culture of planning has been rooted in China's DNA and has been crucial in developing leaders who are in tune with the demands of the times. A prime example is President Xi. His acute thinking has enabled
More news about: Global Times
Jun 16, 2025, 09:00 ET Omnia Medical Reaches Settlement as PainTEQ Admits Breach and Patent Infringement
arthrodesis. We continue to innovate today with our recent introduction of PsiF90, our PsiFGuard enabling technology, and our upcoming release of PsiF DNA. We remain committed to fair competition in the pain space and look forward to continuing to build on the clinical evidence that has been published utilizing
More news about: Omnia Medical
Jun 16, 2025, 08:30 ET SynXis Concierge.AI Supercharges Direct Bookings and Guest Engagement with Generative AI
conditioning, hydraulic elevators, and hot and cold running water in guest rooms – pushing the boundaries of what's possible has always been part of our DNA," says Langham Hospitality Group Senior Vice President – Strategy, Technology and Innovation Sean Seah. "Sabre's SynXis Concierge.AI solution greatly
More news about: Sabre Corporation
Jun 16, 2025, 07:38 ET Innovative Molecules Completes Enrollment of Phase 1b Clinical Trial of IM-250
IM-250 is a novel, orally available, selective HSV-helicase primase inhibitor. Helicase primase inhibitors block DNA unwinding in the replication fork during viral DNA-replication by a potentially uncompetitive mechanism of action. IM-250, due to its optimized molecular structure, is likely
More news about: Innovative Molecules GmbH
Jun 16, 2025, 07:15 ET ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)
internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death. The U.S. Food and Drug
More news about: ADC Therapeutics SA
Jun 16, 2025, 07:00 ET KLOTHO NEUROSCIENCES RAISES OVER $11 MILLION, RETIRES ALL DEBT, AND EXCEEDS NASDAQ STOCKHOLDERS' EQUITY REQUIREMENT
such as ALS, Alzheimer's, and Parkinson's disease. The company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The company is managed by a team of individuals and advisors who are highly experienced
More news about: Klotho Neurosciences, Inc.
Jun 16, 2025, 05:00 ET Philip Morris International's India Affiliate Reiterates its Commitment to 'Grow Talent, Grow Business'
support, and resources for their careers and professional development. These principles are codified in the cultural values, referred to as the PMI DNA - We Care - Self-aware, Inclusive, Empathetic; We are Better Together - Trust, Collaborate, Celebrate; We are Game Changers - Embrace
More news about: IPM India Wholesale Trading Private Limited
Jun 13, 2025, 14:54 ET CureLab Veterinary's ElenaVet™ Gene Therapy Delivers 90% Success in Pet-Dog Osteoarthritis Study
funding, the company anticipates submitting a licensing application within 2–3 years. About ElenaVet™ElenaVet™ is a circular DNA plasmid encoding the SQSTM1/p62 protein, delivered via intramuscular injection. The therapy is designed to up-regulate the body's own anti-inflammatory
More news about: CureLab Veterinary